The reverse split is a last-resort measure to avoid delisting, not a catalyst for recovery. With a $2M market cap, zero revenue, and a history of severe post-filing declines, the stock faces high risk of continued deterioration. The Phase 2/3 trial initiation is a binary catalyst but unlikely to offset the structural distress.
Price Chart
Executive Summary
Silexion Therapeutics announced a 1-for-10 reverse share split effective May 28, 2026, to regain compliance with Nasdaq's minimum bid price requirement. The company also reiterated plans to initiate a Phase 2/3 trial of its lead candidate SIL204 in locally advanced pancreatic cancer this quarter. With a market cap of only $2M and a history of severe stock declines following prior filings, this reverse split is a distress signal that does not address the fundamental clinical and capital challenges.
Key Facts
- 1-for-10 reverse share split effective after market close on May 28, 2026; trading on split-adjusted basis begins May 29, 2026.
- Reverse split intended to maintain compliance with Nasdaq's minimum bid price requirement (Listing Rule 5550(a)(2)).
- Company plans to initiate a Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer in Q2 2026.
- Market cap is approximately $2M, indicating extreme distress.
Financial Impact
Reverse split mechanically reduces share count by 90% but does not change market cap or fundamentals. No financial figures disclosed.
Risk Factors
- Failure to maintain Nasdaq listing even after reverse split if price drops again.
- Clinical trial failure or delay of SIL204 would be catastrophic given single-asset pipeline.
- Extreme dilution risk from future equity financings, as reverse split enables easier capital raising.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301080 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | DEFA14A | $0.1538 | awaiting T+20 | — | $0.1657 (−7.74%) |
Oct 5, 2026 22d ago | DEF 14A | $0.2628 | awaiting T+20 | — | $0.1657 (+36.95%) |
Sep 30, 2026 27d ago | 8-K | $0.2770 | awaiting T+20 | — | $0.1657 (−40.18%) |
Sep 30, 2026 27d ago | Press Release | $0.2773 | awaiting T+20 | — | $0.1657 (+40.25%) |
Sep 29, 2026 28d ago | 8-K | $0.3180 $0.1650 | ▲ +48.11% | ▲ +48.77% | $0.1657 (+47.89%) |
Sep 29, 2026 28d ago | Press Release | $0.3184 $0.1657 | ▲ +47.96% | ▲ +48.67% | $0.1657 (+47.96%) |
Sep 28, 2026 29d ago | 8-K | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1657 (−33.29%) |
Sep 28, 2026 29d ago | Press Release | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1657 (−33.29%) |
Sep 25, 2026 4w ago | 8-K | $0.2484 $0.1746 | ▲ +29.71% | ▲ +29.68% | $0.1657 (+33.29%) |
Aug 14, 2026 10w ago | 8-K | $0.4202 $0.3854 | ▲ +8.28% | ▲ +6.29% | $0.1657 (+60.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers